SOSharon Oud

Sharon Oud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sharon Oud has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Çağdaş Ünlü

    Department of Surgery, Northwest Clinics, Alkmaar, The Netherlands; Department of Surgery, Red Cross Hospital, Beverwijk, The Netherlands

    3 shared publications
  • Michiel A. Schreve

    Department of Surgery, Northwest Clinics, Alkmaar, The Netherlands; Department of Surgery, Red Cross Hospital, Beverwijk, The Netherlands

    2 shared publications
  • Tamana Alozai

    Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands

    2 shared publications
  • Clarissa J van Vlijmen

    Department of Phlebology, Skin and Vein Clinic Oosterwal, Alkmaar, The Netherlands

    1 shared publication
  • Clarissa J van Vlijmen

    Skin and Vein Clinic Oosterwal, Alkmaar, Netherlands

    1 shared publication
  • D. Kok

    Trauma Unit, Department of Surgery, Amsterdam University Medical Centers, Location AMC, Meibergdreef 9, 1105, AZ Amsterdam, the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Anatomic Success of Treatment Modalities for Small Saphenous Vein Incompetence: A Systematic Review and Network Meta-analysis

    by Sharon Oud, Tamana Alozai, Faridi S. Jamaludin, Susan van Dieren, Michiel A. Schreve, Michael C. Mooij, Ron Balm, Çağdaş Ünlü


  • Incidence, treatment variation and outcomes of Rollercoaster reflux

    by Sharon Oud, Michael C Mooij, Michiel A Schreve, Clarissa J van Vlijmen, Çağdaş Ünlü

    Objective: Paradoxical reflux, which is most commonly seen in the Giacomini vein, is also referred to as Rollercoaster reflux (RCR). RCR is a rare phenomenon, infrequently reported in literature and lacking standardized treatments. The aim of this study was to describe the incidence, treatment variation, and outcomes of RCR in a high-volume centre, specialized in skin and venous disease. Methods: All patients suspected of venous incompetence who presented at Skin and Vein Clinic Oosterwal between July 2022 and July 2023 were retrospectively screened to determine if they had RCR. All eligible patients were invited to participate in the cohort study, regardless of treatment or treatment type (ultrasound-guided foam sclerotherapy [UGFS], endovenous thermal ablation [EVTA], or compression therapy). A duplex-ultrasound was performed and the VEINES-QoL/Sym questionnaire was completed. The primary outcomes were RCR incidence and type of RCR. Secondary outcomes were assessed at 1-year follow-up and included anatomical success rates, complications, quality of life (QoL) and patient-satisfaction scores. Results: The incidence of RCR was 1.1% (62/5.718 patients). Fifty-one limbs of 50 patients were included. Anatomical success after 1 year was 73.3% for limbs treated with UGFS and 96.6% for limbs treated with EVTA. The most common complication for UGFS was hyperpigmentation (40.0%) and for EVTA was nerve injury (10.3%). QoL improved across all treatment groups and there were no significant differences in patient satisfaction scores. Conclusion: RCR is a rare phenomenon occurring in only 1.1% of patients suspected of venous incompetence. Although EVTA had a higher anatomical success rate compared to UGFS for the treatment of RCR, QoL improved across all treatment groups.


  • Open Access

    Long-term outcomes of mechanochemical ablation using the Clarivein device for the treatment of great saphenous vein incompetence

    by Sharon Oud, Tamana Alozai, Yee Lai Lam, Çağdaş Ünlü, Michael Mooij, Michiel A. Schreve


  • Open Access

    Comparing mechanochemical endovenous ablation using Flebogrif with endovenous laser ablation in the treatment of primary great saphenous vein incompetence: protocol for a multicentre, open-label, non-inferiority, observer-blinded, randomised controlled trial (REBORN trial)

    by Sharon Oud, Tamana Alozai, Michiel A Schreve, Michael C Mooij, Clarissa J van Vlijmen, Çağdaş Ünlü

    Introduction Endovenous laser ablation (EVLA) is associated with an excellent outcome in the treatment of great saphenous vein (GSV) incompetence. However, the use of thermal ablation requires tumescent anaesthesia and is associated with a risk of thermal damage. Mechanochemical endovenous ablation (MOCA) is a non-thermal ablation (NTA) alternative, which combines mechanical endothelial damage with the infusion of a sclerosant liquid or foam. Tumescent anaesthesia is not required. Preliminary experiences with MOCA using the Clarivein device show less intraprocedural and postprocedural pain and a faster clinical improvement compared with EVLA. Flebogrif (Balton, Poland) is a relatively new MOCA device. To determine the role of MOCA using Flebogrif, a well-designed, randomised controlled clinical trial of sufficient sample size and follow-up time is required. In this article, we provide the study protocol for the REBORN trial, aiming to demonstrate that MOCA using Flebogrif is not inferior to EVLA for the outcome of anatomical success in the treatment of GSV incompetence. Methods and analysis This multicentre, open-label, non-inferiority, observer-blinded, randomised controlled trial randomises patients who are diagnosed with GSV incompetence and aged 18–80 years between Flebogrif and EVLA. 310 patients in 3 participating centres (Northwest Clinics Alkmaar, Skin and Vein Clinic Oosterwal Alkmaar and Red Cross Hospital Beverwijk) will be included. The primary outcome is anatomical success at 12 months. Secondary outcomes are intraprocedural pain, operation time, technical success, postprocedural pain, safety, anatomical success during other follow-up moments, complications, clinical success, aesthetic result, disease-specific quality of life, reinterventions, anterior accessory saphenous vein reflux and neovascularisation. Patients will be followed up at 1 week, 1, 6, 12, 24 and 60 month(s) after treatment. Ethics and dissemination The institutional review board (Medical Ethical Review Committee of the Vrije Universiteit Medical Center) approved this study on 17 May 2021 under case number 2020.0740. Written informed consent is obtained by the coordinating investigator from all participants prior to study enrolment. After completion of the trial, the results will be submitted to an international scientific journal for peer-reviewed publication. Trial registration number Overzicht van Medisch-wetenschappelijk Onderzoek in Nederland, NL-OMON25145, previously NL9527; Centrale Commissie Mensgebonden Onderzoek, NL74491.029.20.


  • Open Access

    Delayed diagnosed injuries in trauma patients after initial trauma assessment with a total-body computed tomography scan

    by D. Kok, S. Oud, G.F. Giannakópoulos, M.J. Scheerder, L.F.M. Beenen, J.A. Halm, K. Treskes